For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 18,963 | 13,121* | 16,044 | 15,383 |
| General and administrative | 10,636 | 7,293* | 7,761 | 6,523 |
| Total operating expenses | 29,599 | 20,414 | 23,805 | 21,906 |
| Loss from operations | -29,599 | -20,414* | -23,805 | -21,906 |
| Interest income | 2,820 | 2,611* | 3,456 | 3,667 |
| Other income | 0 | 56* | 71 | 171 |
| Total other income | 2,820 | 2,667* | 3,527 | 3,838 |
| Net loss | -26,779 | -17,748* | -20,278 | -18,068 |
| Unrealized gain on marketable securities | -624 | -6 | 237 | -118 |
| Total other comprehensive gain | -624 | -6* | 237 | -118 |
| Comprehensive loss | -27,403 | -17,755 | -20,041 | -18,186 |
| Basic EPS | -0.6 | -0.563 | -0.46 | -410 |
| Diluted EPS | -0.6 | -0.563 | -0.46 | -410 |
| Basic Average Shares | 44,921,984 | 31,514,439 | 44,255,053 | 44,116,997 |
| Diluted Average Shares | 44,921,984 | 31,514,439 | 44,255,053 | 44,116,997 |
Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. (SION)